These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 8576917)

  • 1. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.
    Hipskind PA; Howbert JJ; Bruns RF; Cho SS; Crowell TA; Foreman MM; Gehlert DR; Iyengar S; Johnson KW; Krushinski JH; Li DL; Lobb KL; Mason NR; Muehl BS; Nixon JA; Phebus LA; Regoli D; Simmons RM; Threlkeld PG; Waters DC; Gitter BD
    J Med Chem; 1996 Feb; 39(3):736-48. PubMed ID: 8576917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action.
    Iyengar S; Hipskind PA; Gehlert DR; Schober D; Lobb KL; Nixon JA; Helton DR; Kallman MJ; Boucher S; Couture R; Li DL; Simmons RM
    J Pharmacol Exp Ther; 1997 Feb; 280(2):774-85. PubMed ID: 9023291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.
    Walpole C; Ko SY; Brown M; Beattie D; Campbell E; Dickenson F; Ewan S; Hughes GA; Lemaire M; Lerpiniere J; Patel S; Urban L
    J Med Chem; 1998 Aug; 41(17):3159-73. PubMed ID: 9703462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.
    Gerspacher M; Lewis C; Ball HA; Howes C; Subramanian N; Ryffel K; Fozard JR
    J Med Chem; 2003 Jul; 46(16):3508-13. PubMed ID: 12877589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.
    Hale JJ; Mills SG; MacCoss M; Finke PE; Cascieri MA; Sadowski S; Ber E; Chicchi GG; Kurtz M; Metzger J; Eiermann G; Tsou NN; Tattersall FD; Rupniak NM; Williams AR; Rycroft W; Hargreaves R; MacIntyre DE
    J Med Chem; 1998 Nov; 41(23):4607-14. PubMed ID: 9804700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the interaction of diacylpiperazine antagonists with the human neurokinin-1 receptor: identification of a common binding site for structurally dissimilar antagonists.
    Cascieri MA; Shiao LL; Mills SG; MacCoss M; Swain CJ; Yu H; Ber E; Sadowski S; Wu MT; Strader CD
    Mol Pharmacol; 1995 Apr; 47(4):660-5. PubMed ID: 7536886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
    Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
    J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 3-phenylpiperidine-4-carboxamides as highly potent and orally long-acting neurokinin-1 receptor antagonists with reduced CYP3A induction.
    Shirai J; Sugiyama H; Morimoto S; Maezaki H; Yamamoto Y; Okanishi S; Kamo I; Matsumoto S; Ishigami K; Inatomi N; Imanishi A; Kawamoto M; Tarui N; Hashimoto T; Ikeura Y
    Bioorg Med Chem; 2012 Jan; 20(2):962-77. PubMed ID: 22189275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in vitro activities of highly potent and selective tripeptide antagonists of the neurokinin NK-1 receptor.
    Caliendo G; Greco G; Grieco P; Perissutti E; Santagada V; Calignano A; Mancuso F; Novellino E
    Farmaco; 1995 Nov; 50(11):755-9. PubMed ID: 8593172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
    Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
    Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
    Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
    Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
    Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain.
    Gonzalez MI; Field MJ; Hughes J; Singh L
    J Pharmacol Exp Ther; 2000 Aug; 294(2):444-50. PubMed ID: 10900217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
    Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET
    J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
    J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insertion of an aspartic acid moiety into cyclic pseudopeptides: synthesis and biological characterization of potent antagonists for the human Tachykinin NK-2 receptor.
    Fedi V; Altamura M; Balacco G; Canfarini F; Criscuoli M; Giannotti D; Giolitti A; Giuliani S; Guidi A; Harmat NJ; Nannicini R; Pasqui F; Patacchini R; Perrotta E; Tramontana M; Triolo A; Maggi CA
    J Med Chem; 2004 Dec; 47(27):6935-47. PubMed ID: 15615542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.
    Becker DP; Flynn DL; Moormann AE; Nosal R; Villamil CI; Loeffler R; Gullikson GW; Moummi C; Yang DC
    J Med Chem; 2006 Feb; 49(3):1125-39. PubMed ID: 16451077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
    Biswas K; Li A; Chen JJ; D'Amico DC; Fotsch C; Han N; Human J; Liu Q; Norman MH; Riahi B; Yuan C; Suzuki H; Mareska DA; Zhan J; Clarke DE; Toro A; Groneberg RD; Burgess LE; Lester-Zeiner D; Biddlecome G; Manning BH; Arik L; Dong H; Huang M; Kamassah A; Loeloff R; Sun H; Hsieh FY; Kumar G; Ng GY; Hungate RW; Askew BC; Johnson E
    J Med Chem; 2007 May; 50(9):2200-12. PubMed ID: 17408249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
    Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
    J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.